Oncolytics Biotech (ONCY) closed at $0.47 on October 26, 2026, down 5.7% from the previous close, on volume of 688,094 shares (30-day average 1,219,720).
Data as of October 26, 2026.
Globe Newswire (Tue, 20-Oct 9:35 AM ET)
Oncolytics Biotech Provides Update on GOBLET Study Clinical Data and Final PanCAN Grant Payment
Globe Newswire (Wed, 14-Oct 9:30 AM ET)
Globe Newswire (Mon, 12-Oct 4:05 PM ET)
Globe Newswire (Tue, 29-Sep 9:30 AM ET)
Globe Newswire (Mon, 28-Sep 9:30 AM ET)
Three Nasdaq Cancer Developers Under $10 Advance Clinical Programs
Globe Newswire (Fri, 11-Sep 8:45 AM ET)
Globe Newswire (Thu, 10-Sep 8:15 AM ET)
Globe Newswire (Tue, 18-Aug 9:00 AM ET)
Oncolytics Biotech Advances toward Potential FDA Registration with Expanded Colorectal Cancer Trial
Market Chameleon (Mon, 13-Jul 6:30 AM ET)
ONCY Cancer Trial Achieves 30% Response Rate—More Than Double the FDA Standard
Market Chameleon (Tue, 28-Oct 7:57 AM ET)
Oncolytics Biotech Inc is a clinical-stage biopharmaceutical company. The company is focused on the discovery and development of pharmaceutical products for the treatment of cancers that have not been treated with therapeutics. It is developing pelareorep, an immunotherapeutic agent that improves the ability of the immune system to fight cancer, making tumors more susceptible to a broad range of oncology treatments. The other projects in the company's pipeline include Bracelet-1 for the treatment of Breast Cancer, Goblet cohort-1, and Goblet cohort-5 for the treatment of Gastro-Intestinal Cancer, among others.
Oncolytics Biotech trades on the NASDAQ stock market under the symbol ONCY.
As of October 26, 2026, ONCY stock price declined to $0.47 with 688,094 million shares trading.
ONCY has a beta of 1.81, meaning it tends to be more sensitive to market movements. ONCY has a correlation of 0.09 to the broad based SPY ETF.
ONCY has a market cap of $60.34 million. This is considered a Micro Cap stock.
In the last 3 years, ONCY traded as high as $1.80 and as low as $.33.
The top ETF exchange traded funds that ONCY belongs to (by Net Assets): QQQS.
ONCY has underperformed the market in the last year with a return of -60.6%, while the SPY ETF gained +14.1%. In the last 3 month period, ONCY fell short of the market, returning -41.7%, while SPY returned +3.8%. However, in the most recent 2 weeks ONCY has outperformed the stock market by returning 0.0%, while SPY returned -1.6%.
ONCY support price is $.47 and resistance is $.53 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that ONCY shares will trade within this expected range on the day.
